RepliCel Life Sciences Inc. (V:RP)

Independent Testing Performed by Innovacell Demonstrates the DermaPrecise™ Control Leads to Unparalleled Post-Injection Cell Survival and Viability Consistency

Jul 28, 2022 06:00 am ET

RepliCel’s Manufacturing Inspected by Japan’s PMDA

After over a year of pandemic-related delays, representatives of Japan's PMDA, attended at the Company's contract manufacturing facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell therapy products

Jul 26, 2022 04:45 pm ET

CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing

This press release replaces the press release disseminated July 26, 2022 at 06:00 EDT. The press release contained the wrong image - one intended for a future press release. The corrected press release with the proper image is below:

Jul 26, 2022 06:00 am ET

Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing

Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters using donated human tissue

Jan 10, 2022 06:00 am ET

RepliCel Announces Material Patent Milestones

New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets

Dec 21, 2021 05:00 pm ET

RepliCel Closed Final Tranche of Strategic Investment Commitment

VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has closed the final tranche of the investment by MainPointe Pharmaceuticals ("MainPointe") as outlined in the share purchase agreement signed by the parties earlier this year.

Dec 21, 2021 11:10 am ET

RepliCel Terminates License Agreement with Shiseido

VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today that the dispute between Shiseido and RepliCel has led to the Company electing to terminate the license agreement with Shiseido. The Company's decision is a legal step in its pursuit of a resolution of its disagreement with Shiseido that is the subject of ongoing arbitration proceedings

Nov 11, 2021 06:00 am ET

RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing

Independent dermatology research experts at Monasterium Laboratory GmbH will test, analyze and validate various injection parameters using donated human tissue

Nov 09, 2021 06:00 am ET

RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team

RepliCel's CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearance

Oct 28, 2021 06:00 am ET

RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line

Trademark registrations kickoff pre-commercial planning

Oct 27, 2021 06:00 am ET

RepliCel Announces Dermal Injector Update

Testing progresses to next-phase; results lead to some component upgrades to ensure optimal performance, quality compliance, and commercial-scale production capabilities

Oct 18, 2021 06:00 am ET

RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy

After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseido's full compliance with the agreement or return of the license and all collaboration data and innovations related to its cell therapy treatment for male and female pattern hair loss.

Oct 12, 2021 06:00 am ET

RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor

Kunihiko Suzuki, one of the leading pioneers in Japan's emerging regenerative medicine industry, commits to a role as Senior Strategic Advisor to RepliCel's Board of Directors

Sep 16, 2021 06:00 am ET

RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents

VANCOUVER, BC / ACCESSWIRE / September 16, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that the first-stage of a research project with the University of Victoria Centre for Biomedical Engineering ("UVic") has led to significant milestones in terms of technology advancements, patent filings, grant funding, and a license option agreement.

Jul 07, 2021 06:00 am ET

RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies

Clinical development of RepliCel's skin rejuvenation and tendon regeneration injectables continues to meet milestones on path to commercialization in Japan

Jun 15, 2021 06:00 am ET

RepliCel Adds Independent Director

Board of Directors Strengthens Its Independence Oversight and Updates its Stock Options

May 25, 2021 06:00 am ET

RepliCel Launches Testing of Dermal Injector Units

Initial units delivered and first phase of functional testing nearly complete

May 19, 2021 06:00 am ET

RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies

Clinical Research Organization, Accerise Inc., Has Been Retained To Work With RepliCel and Its Other Service Providers To Prepare Study Documentation, Plans, and Approvals for Clinical Evaluation by Multiple Clinical Sites in Japan

May 17, 2021 06:00 am ET

RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor

Professor Akimichi Morita, Vice Director of Nagoya City University Hospital, will lead RepliCel's Skin Rejuvenation Clinical Testing in Japan

May 11, 2021 06:00 am ET

RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map

Early identification of unique cell markers is expected to have valuable impact on patents, clinical efficacy, and manufacturing optimization

May 05, 2021 06:00 am ET

RepliCel Announces Record Year in Patents Granted

Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration Technologies

May 03, 2021 06:00 am ET

RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)

Professor Tsukasa Kumai, member of the Japan's Olympic Committee Medical and Scientific Staff, will lead RepliCel's Tendon Regeneration Clinical Testing in Japan

Apr 29, 2021 06:00 am ET

RepliCel Closes Second Tranche of Strategic Investment Commitment

MainPointe Pharmaceuticals Completes Largest Scheduled Share Purchases per Investment Agreement

Feb 18, 2021 06:00 am ET

RepliCel Presents Its Technology Development and Commercialization Plans for Japan at Kanagawa Regenerative Medicine Industry Conference

Kanagawa Regeneration and Cell Medical Industry Network Organizers Invite RepliCel to Participate in Foreign Company Pitch Session

Feb 10, 2021 06:00 am ET

RepliCel Closes First Tranche of Strategic Investment Commitment

MainPointe Pharmaceuticals Completes Initial Share Purchase per Investment Agreement

Feb 08, 2021 06:00 am ET

RepliCel CEO Provides Corporate Update

Targets for 2021 include dermal injector commercial launch, new partnerships, new innovation initiatives, and launch of more clinical testing

Jan 25, 2021 06:00 am ET

RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement

MainPointe Deal Positions RepliCel for entry into the U.S. market and significant milestones in Japan

Nov 10, 2020 06:00 am ET

RepliCel Announces a Binding Term Sheet For Strategic Investment and U.S. Partnership

RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, announced today its intent to enter into a strategic partnership with...

Sep 14, 2020 05:45 pm ET

RepliCel Q3 2020 Management Update

RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its Board and...

Dec 23, 2019 05:00 am ET

RepliCel Announces its Incoming Board of Directors

Successful Annual General Meeting Confirms Director Slate for 2020

Nov 26, 2019 05:00 am ET

RepliCel Provides 2019 Year-End Update

Notable Milestones for the Company's Programs

Sep 24, 2019 06:00 am ET

Clinical Data Published from RepliCel's Skin Rejuvenation Study

A paper entitled, "Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study", has been published summarizing the data from RepliCel's clinical trial of RCS-01

Sep 24, 2019 06:00 am ET

Clinical Data Published from RepliCel's Skin Rejuvenation Study

A paper entitled, "Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study", has been published summarizing the data from RepliCel's clinical trial of RCS-01

Sep 10, 2019 06:00 am ET

RepliCel's Partner, YOFOTO (China) Health, Unveils its Inaugural Cell Therapy Manufacturing Facility in China

YOFOTO (China) Health Now Commissioning its Manufacturing Facility in Preparation for Technology Transfer of Skin and Tendon Product Manufacturing and Applications for Clinical Trials

Sep 10, 2019 06:00 am ET

RepliCel's Partner, YOFOTO (China) Health, Unveils its Inaugural Cell Therapy Manufacturing Facility in China

YOFOTO (China) Health Now Commissioning its Manufacturing Facility in Preparation for Technology Transfer of Skin and Tendon Product Manufacturing and Applications for Clinical Trials

Aug 29, 2019 06:00 am ET

RepliCel Life Sciences Retains Dermatology Sales and Marketing Executive to Guide the Global Commercial Strategy for its Automated Dermal Injector

Management strengthens its commitment to a successful upcoming market launch of RepliCel's dermal injector and consumables product line by addition of Damien King

Aug 29, 2019 06:00 am ET

RepliCel Life Sciences Retains Dermatology Sales and Marketing Executive to Guide the Global Commercial Strategy for its Automated Dermal Injector

Management strengthens its commitment to a successful upcoming market launch of RepliCel's dermal injector and consumables product line by addition of Damien King

Apr 16, 2019 06:00 am ET

RepliCel Secures Several New Patents for its Regenerative Medicine Technologies

Tendon Regeneration, Skin Rejuvenation and Dermal Injector Patents Granted in the United States, Europe, South Africa, Hong Kong, China, and Japan

Apr 16, 2019 06:00 am ET

RepliCel Secures Several New Patents for its Regenerative Medicine Technologies

Tendon Regeneration, Skin Rejuvenation and Dermal Injector Patents Granted in the United States, Europe, South Africa, Hong Kong, China, and Japan

Mar 26, 2019 06:00 am ET

RepliCel's Licensee Building Momentum in China with Facility and Team

YOFOTO (China) Health Announces Initiation of Facility Build-Out, New Hires, and Preparation to Submit Applications to China's Regulators

Mar 26, 2019 06:00 am ET

RepliCel's Licensee Building Momentum in China with Facility and Team

YOFOTO (China) Health Announces Initiation of Facility Build-Out, New Hires, and Preparation to Submit Applications to China's Regulators

Mar 19, 2019 06:00 am ET

RepliCel Reignites its First-in-Japan Strategy

Next-stage trials in Japan present market launch opportunities for RepliCel's skin and tendon products

Mar 19, 2019 06:00 am ET

RepliCel Reignites its First-in-Japan Strategy

Next-stage trials in Japan present market launch opportunities for RepliCel's skin and tendon products

Mar 05, 2019 05:00 am ET

RepliCel CEO Provides 2019 Shareholder Update

With a new strategic plan, RepliCel prioritizes focus on commercial revenue

Mar 05, 2019 05:00 am ET

RepliCel CEO Provides 2019 Shareholder Update

With a new strategic plan, RepliCel prioritizes focus on commercial revenue

Nov 06, 2018 05:00 am ET

RepliCel Life Sciences Appoints Head of Clinical and Regulatory Affairs

Appointment of Dr. Goessens-Rueck strengthens management team and fulfils commitment to promote female leadership in biotech

Nov 06, 2018 05:00 am ET

RepliCel Life Sciences Appoints Head of Clinical and Regulatory Affairs

Appointment of Dr. Goessens-Rueck strengthens management team and fulfils commitment to promote female leadership in biotech

Oct 18, 2018 06:00 am ET

RepliCel Announces Federal Grant Funding for Collaboration with the University of Victoria, Canada

The National Sciences and Engineering Research Council of Canada has funded a University of Victoria project aimed at collaborating with RepliCel to optimize cell culture and manufacturing technologies

Oct 18, 2018 06:00 am ET

RepliCel Announces Federal Grant Funding for Collaboration with the University of Victoria, Canada

Oct 17, 2018 06:00 am ET

RepliCel Life Sciences Appoints New Chief Financial Officer

VANCOUVER, Oct. 17, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announces that its board of directors has appointed Simon Ma as the Chief Financial Officer of the Company. Mr. Ma is the current Director of Finance and succeeds Tom Kordyback who has resigned as the Chief Financial Officer to enjoy his full-time retirement from professional service.

Oct 17, 2018 06:00 am ET

RepliCel Life Sciences Appoints New Chief Financial Officer

VANCOUVER, Oct. 17, 2018 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announces that its board of directors has appointed Simon Ma as the Chief Financial Officer of the Company. Mr. Ma is the current Director of Finance and succeeds Tom Kordyback who has resigned as the Chief Financial Officer to enjoy his full-time retirement from professional service.

Oct 15, 2018 06:00 am ET

RepliCel CEO Provides Updated Outlook

Partnership and Investment Fuel Plans for Upcoming Advancements

Oct 15, 2018 06:00 am ET

RepliCel CEO Provides Updated Outlook

Partnership and Investment Fuel Plans for Upcoming Advancements

Oct 11, 2018 06:00 am ET

RepliCel Life Sciences Completes Financing with YOFOTO (China) Health

YOFOTO (China) Health and RepliCel Life Sciences finalize investment and commence collaboration activity in Greater China

Oct 11, 2018 06:00 am ET

RepliCel Life Sciences Completes Financing with YOFOTO (China) Health

YOFOTO (China) Health and RepliCel Life Sciences finalize investment and commence collaboration activity in Greater China

Sep 24, 2018 06:00 am ET

RepliCel Life Sciences and YOFOTO (China) Health Obtain All Approvals Needed to Complete Investment

YOFOTO (China) Health and RepliCel Life Sciences now cleared to close investment transaction and commence collaboration activity in Greater China

Sep 24, 2018 06:00 am ET

RepliCel Life Sciences and YOFOTO (China) Health Obtain All Approvals Needed to Complete Investment

YOFOTO (China) Health and RepliCel Life Sciences now cleared to close investment transaction and commence collaboration activity in Greater China

Jul 11, 2018 06:00 am ET

RepliCel Life Sciences Announces Signed Licensing and Co-Development Deal for Greater China

Skin rejuvenation and tendon regeneration products to be commercialized in Greater China in partnership with YOFOTO (China) Health Industry Co. Ltd

Jul 11, 2018 06:00 am ET

RepliCel Life Sciences Announces Signed Licensing and Co-Development Deal for Greater China

Skin rejuvenation and tendon regeneration products to be commercialized in Greater China in partnership with YOFOTO (China) Health Industry Co. Ltd

May 02, 2018 06:00 am ET

RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO

A revised binding term sheet reflects improved terms, and positions the parties for closing the transaction

May 02, 2018 06:00 am ET

RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO

A revised binding term sheet reflects improved terms, and positions the parties for closing the transaction

Jan 25, 2018 05:00 am ET

RepliCel CEO Provides 2018 Shareholder Update

With a new Asian partnership and 2017 deliverables met, RepliCel is primed and ready for expansion

Jan 25, 2018 05:00 am ET

RepliCel CEO Provides 2018 Shareholder Update

With a new Asian partnership and 2017 deliverables met, RepliCel is primed and ready for expansion

Jan 16, 2018 05:00 am ET

RepliCel Life Sciences Lands Commitment for Key Investment Partnership

YOFOTO (China) Health Industry Co. Ltd to Invest in Becoming RepliCel's Strategic Partner for Greater China

Jan 16, 2018 05:00 am ET

RepliCel Life Sciences Lands Commitment for Key Investment Partnership

YOFOTO (China) Health Industry Co. Ltd to Invest in Becoming RepliCel's Strategic Partner for Greater China

Oct 19, 2017 06:00 pm ET

RepliCel Life Sciences Successfully Closes Financing

Shareholders commit to non-brokered private placement in clear support of the Company's partnership strategy

Sep 22, 2017 09:24 pm ET

RepliCel Retains Hybrid Financial for Investor Relations

VANCOUVER, Sept. 22, 2017 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has retained Hybrid Financial Inc. ("Hybrid") to provide certain investor relations services (the "Services") to the Company, commencing September 26, 2017.

Sep 22, 2017 09:24 pm ET

RepliCel Retains Hybrid Financial for Investor Relations

VANCOUVER, Sept. 22, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has retained Hybrid Financial Inc. ("Hybrid") to provide certain investor relations services (the "Services") to the Company, commencing September 26, 2017.

Sep 13, 2017 07:00 am ET

RepliCel's Partnership Initiatives Mature into Licensing Negotiations

Due diligence and confidential discussions now moving into negotiations for products in both the tendon repair and aesthetics franchises

Sep 13, 2017 07:00 am ET

RepliCel's Partnership Initiatives Mature into Licensing Negotiations

Due diligence and confidential discussions now moving into negotiations for products in both the tendon repair and aesthetics franchises

Sep 07, 2017 07:00 am ET

RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector

Delivery of RepliCel's patented prototypes kick-starts functional testing, matures licensing discussions, and confirms commercialization schedule

Sep 07, 2017 07:00 am ET

RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector

Delivery of RepliCel's patented prototypes kick-starts functional testing, matures licensing discussions, and confirms commercialization schedule

Aug 24, 2017 08:45 am ET

Streetwise Reports Examines Analyst's View that Cell Therapy Company's Move Decreases Risk

A regenerative medicine company has signed on to the ThawSTAR Early Adopter Program, a move analyst Douglas Loe of Echelon Wealth Partners terms "positive logistically" to development risk.Included in this article is: RepliCel Life Sciences Inc....

Aug 10, 2017 07:00 am ET

Prominent Skin Aging Researcher Provides Insights into RepliCel's Clinical Data

"We believe that this novel therapy has the potential to rejuvenate skin in a way we've never seen before", states key opinion leader in dermatology research

Aug 10, 2017 07:00 am ET

Prominent Skin Aging Researcher Provides Insights into RepliCel's Clinical Data

"We believe that this novel therapy has the potential to rejuvenate skin in a way we've never seen before", states key opinion leader in dermatology research

Jun 13, 2017 07:00 am ET

RepliCel Collaborates with University of British Columbia to Build World-Class Hair Follicle Cell Data Map

Data from this project expected to take RepliCel's products to next level of potential commercial viability

Jun 13, 2017 07:00 am ET

RepliCel Collaborates with University of British Columbia to Build World-Class Hair Follicle Cell Data Map

Data from this project expected to take RepliCel's products to next level of potential commercial viability

May 25, 2017 07:00 am ET

RepliCel CEO Provides Company Outlook

A data-rich 2017 positions RepliCel for maturity through the next phase of its product development, research programs, and revenue generation

May 25, 2017 07:00 am ET

RepliCel CEO Provides Company Outlook

A data-rich 2017 positions RepliCel for maturity through the next phase of its product development, research programs, and revenue generation

Apr 25, 2017 07:00 am ET

United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies

With exclusive U.S. rights to RCI-02 patents, RepliCel edges its nearest-term commercial asset closer to launch in large aesthetic market

Apr 25, 2017 07:00 am ET

United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies

With exclusive U.S. rights to RCI-02 patents, RepliCel edges its nearest-term commercial asset closer to launch in large aesthetic market

Apr 13, 2017 08:45 am ET

The Life Sciences Report Examines How Positive Trial Results Boost RepliCel's Profile

Positive results from RepliCel Life Sciences Inc.'s (TSX VENTURE: RP) (OTCQB: REPCF) Phase 1 trial for the treatment of aging and sun-damaged skin follow the release in the past few weeks of positive data from trials for chronic tendon problems and...

Apr 04, 2017 07:00 am ET

Positive Results from RepliCel's RCS-01 Phase I Skin Trial are the Company's Most Compelling to Date

Interim trial results lead researchers to conclude that the injection of RCS-01 is not only very safe, but also has the potential to reverse effects of aging skin, representing a natural alternative to existing anti-aging treatments

Apr 04, 2017 07:00 am ET

Positive Results from RepliCel's RCS-01 Phase I Skin Trial are the Company's Most Compelling to Date

Mar 28, 2017 07:00 am ET

RepliCel's Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems

First-in-human clinical study meets primary endpoint demonstrating product safety and clinical potential for tendon regeneration and healing

Mar 28, 2017 07:00 am ET

RepliCel's Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems

First-in-human clinical study meets primary endpoint demonstrating product safety and clinical potential for tendon regeneration and healing

Mar 17, 2017 08:45 am ET

The Life Sciences Report Examines RepliCel's Phase 1 Trial for Hair Loss Completed Successfully

RepliCel Life Sciences Inc.'s (TSX VENTURE: RP) (OTCQB: REPCF) successful conclusion of its Phase 1 trial for hair loss sets it up for the next steps in the drug's development.Included in this article is: RepliCel Life Sciences Inc. RepliCel Life...

Mar 14, 2017 07:00 am ET

RepliCel's Phase 1 Clinical Trial for Hair Loss Succeeds in Meeting Primary Endpoints

Five-year safety data firmly establishes product safety and confirms ongoing clinical and product development strategy

Mar 14, 2017 07:00 am ET

RepliCel's Phase 1 Clinical Trial for Hair Loss Succeeds in Meeting Primary Endpoints

Five-year safety data firmly establishes product safety and confirms ongoing clinical and product development strategy

Mar 07, 2017 08:59 am ET

RepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization

VANCOUVER, March 7, 2017 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a clinical stage regenerative medicine company developing unique biologic products for pattern baldness and thinning hair, aging and sun-damaged skin, and chronic tendon degeneration, today announced the company has retained The FreeMind Group ("FreeMind"), a premier international firm that assists life science organizations in securing non-dilutive funding from granting agencies and private foundations. RepliCel aims to secure non-dilutive capital to support researc

Mar 07, 2017 08:59 am ET

RepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization

VANCOUVER, March 7, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a clinical stage regenerative medicine company developing unique biologic products for pattern baldness and thinning hair, aging and sun-damaged skin, and chronic tendon degeneration, today announced the company has retained The FreeMind Group ("FreeMind"), a premier international firm that assists life science organizations in securing non-dilutive funding from granting agencies and private foundations. RepliCel aims to secure non-dilutive capital to support

Mar 06, 2017 07:08 pm ET

RepliCel Life Sciences Announces Re-pricing of Warrants

RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (OTCQB: REPCD)(TSX VENTURE: RP)(FRANKFURT: P6P2), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announces that it has applied to the TSX Venture Exchange (the "Exchange") for an amendment to the exercise price of 148,226 non-transferable share purchase warrants (the "April Warrants") expiring April 10, 2017 from $5.00 to $1.14 and 173,900 non-transferable share purchase warrants (the "November Warrants") expiring on November 20,

Mar 06, 2017 07:08 pm ET

RepliCel Life Sciences Announces Re-pricing of Warrants

Feb 28, 2017 06:00 am ET

RepliCel Signs Two Key Service Partnerships for Final Prototype Manufacturing and Testing of its Dermal Injector

Two European firms team up to lead RepliCel's next-generation dermal injector (RCI-02) to market-ready status

Feb 28, 2017 06:00 am ET

RepliCel Signs Two Key Service Partnerships for Final Prototype Manufacturing and Testing of its Dermal Injector

Two European firms team up to lead RepliCel's next-generation dermal injector (RCI-02) to market-ready status

Feb 24, 2017 03:41 pm ET

RepliCel Life Sciences Announces Closing of Brokered and Non-brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (OTCQB:REPCF)(TSX VENTURE:RP)(FRANKFURT:P6P2), a clinical stage regenerative...

Feb 09, 2017 08:00 am ET

RepliCel Announces European Patents for its Innovative Dermal Injector Technologies

RCI-02, RepliCel's nearest-term commercial asset, enables game-changing reliability, reproducibility, and programmability of three-dimensional skin injections

Feb 09, 2017 08:00 am ET

RepliCel Announces European Patents for its Innovative Dermal Injector Technologies

RCI-02, RepliCel's nearest-term commercial asset, enables game-changing reliability, reproducibility, and programmability of three-dimensional skin injections

Feb 07, 2017 08:00 am ET

RepliCel Life Sciences Inc. announces Brokered Private Placement

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

Feb 03, 2017 06:00 am ET

RepliCel Appoints Corporate Executive, Hugh Rogers to its Board of Directors

VANCOUVER, Feb. 3, 2017 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) ("RepliCel" or the "Company") is pleased to announce the appointment of Hugh Rogers, to its Board of Directors. Mr. Rogers holds a B.Sc. degree from the University of British Columbia and a Legum Baccalaureus (LLB) degree from University of New Brunswick. He is a member in good standing of the law society of British Columbia.

Feb 03, 2017 06:00 am ET

RepliCel Appoints Corporate Executive, Hugh Rogers to its Board of Directors

VANCOUVER, Feb. 3, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) ("RepliCel" or the "Company") is pleased to announce the appointment of Hugh Rogers, to its Board of Directors. Mr. Rogers holds a B.Sc. degree from the University of British Columbia and a Legum Baccalaureus (LLB) degree from University of New Brunswick. He is a member in good standing of the law society of British Columbia.

Feb 02, 2017 09:00 am ET

The Life Sciences Report Examines Companies Flocking to Japan for Biotech Deals

For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. Tokyo-based Colin Lee Novick, managing director...

Jan 05, 2017 08:00 am ET

RepliCel CEO Provides 2017 Forecast

RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX VENTURE: RP) ("RepliCel" or the "Company"), a clinical-stage regenerative medicine company developing unique biologic products to revolutionize pattern baldness and thinning hair treatment, reverse the effects of aging and sun-damaged skin, and repair chronic tendon degeneration, is pleased to provide an update to shareholders from its President and CEO, Mr. R. Lee Buckler.

Jan 05, 2017 07:58 am ET

RepliCel CEO Provides 2017 Forecast

Oct 31, 2016 06:58 am ET

RepliCel Life Sciences Announces Closing of Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (OTCQB:REPCD) (TSX VENTURE:RP) (FRANKFURT:P6P2), a clinical stage regenerative...

Oct 07, 2016 12:38 pm ET

RepliCel Life Sciences Amends Terms of Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (OTCQB:REPCD)(TSX VENTURE:RP)(FRANKFURT:P6P2), a clinical stage regenerative...

Sep 27, 2016 09:00 am ET

RepliCel Announces Debt Settlement

RepliCel Life Sciences Inc. (OTCQB: REPCD)(TSX VENTURE: RP)(FRANKFURT: P6P2) ("RepliCel" or the "Company"), a clinical-stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to announce its intention to settle debt (the "Debt Settlement") in the aggregate amount of $374,071.63 owed by the Company to certain creditors by the issuance of 719,368 units (each, a "Unit"). Each Unit consists of one common share of the Company (each, a "Share") and one share purchase warrant (each, a

Sep 27, 2016 08:58 am ET

RepliCel Announces Debt Settlement

Sep 26, 2016 05:47 pm ET

RepliCel Provides Update on Shiseido License and Co-Development for RCH-01

Sep 26, 2016 05:47 pm ET

RepliCel Provides Update on Shiseido License and Co-Development for RCH-01

RepliCel Life Sciences Inc. (OTCQB: REPCD)(TSX VENTURE: RP)(FRANKFURT: P6P2) ("RepliCel" or the "Company"), a clinical-stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to provide an update on the licensing and co-development of its RCH-01 product with Shiseido Company.

Sep 14, 2016 03:42 pm ET

RepliCel Life Sciences Announces Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (OTCQB:REPCD)(TSX VENTURE:RP)(FRANKFURT:P6P2), a clinical stage regenerative...

Aug 11, 2016 08:00 am ET

RepliCel Life Sciences Announces Completion of the Final Injection in Its Tendon Repair Clinical Trial

RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (OTCQB: REPCF) (TSX VENTURE: RP) (FRANKFURT: P6P1), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that it has performed the final injection in its clinical trial of RCT-01 treating patients with chronic achilles tendinopathy. The last scheduled patient visit to collect treatment follow-up data will be in late November.

Aug 11, 2016 07:58 am ET

RepliCel Life Sciences Announces Completion of the Final Injection in Its Tendon Repair Clinical Trial

Aug 09, 2016 07:00 pm ET

RepliCel Life Sciences Share Consolidation Approved

RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (OTCQB: REPCF)(TSX VENTURE: RP) (FRANKFURT: P6P1), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that, further to its News Release of July 22, 2016, the TSX Venture Exchange has approved the consolidation of the common shares of the Company (each, a "Share") on the basis of ten (10) pre-consolidation Shares for one (1) post-consolidation Share (the "Consolidation"). The Consolidation will become effective at the opening of

Aug 09, 2016 06:58 pm ET

RepliCel Life Sciences Share Consolidation Approved

Jul 22, 2016 07:05 pm ET

RepliCel Life Sciences Continues Restructuring With Share Structure Consolidation

RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (OTCQB: REPCF)(TSX VENTURE: RP) (FRANKFURT: P6P1), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that its Board of Directors has authorized a plan to proceed with a consolidation of its outstanding common shares (each, a "Share") on the basis of ten (10) pre-consolidation Shares for one (1) post-consolidation Share (the "Consolidation").

Jul 22, 2016 07:05 pm ET

RepliCel Life Sciences Continues Restructuring With Share Structure Consolidation

Jul 21, 2016 08:00 am ET

RepliCel's Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan

RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX VENTURE: RP)(FRANKFURT: P6P1), ("RepliCel" or the "Company"), a clinical-stage regenerative medicine company focused on the development of autologous cell therapies, is pleased that its RCH-01 product, for the treatment of androgenetic alopecia, is now cleared by the Japanese regulatory authorities for use in a clinical research study launching now in Japan.

Jul 21, 2016 07:58 am ET

RepliCel's Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan

Apr 29, 2016 04:00 pm ET

RepliCel Life Sciences Extends Warrant Expiry Dates and Amends Warrant Exercise Price

RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (OTCQB: REPCF)(TSX VENTURE: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today approval by the TSX Venture Exchange (the "TSXV") to extend the term of 3,765,834 share purchase warrants (the "Extended Warrants").

Apr 29, 2016 03:58 pm ET

RepliCel Life Sciences Extends Warrant Expiry Dates and Amends Warrant Exercise Price

RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (OTCQB:REPCF)(TSX VENTURE:RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today approval by the TSX Venture Exchange...

Ad blocking detected

RepliCel Life Sciences Inc. (V:RP)

Business Focus: N/A